What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 1 month ago
Risk of TNFi-related psoriasis in 5088 TNFi Rx children w/ IBD, JIA, or CNO. Compared to non-TNFi exposed, kids on TNFi had an increased PSO risk w/ ADA (IRR 2.70; 1.53-4.75), infliximab (2.34) or etanercept (2.21) & not incr w/ DMARD use https://t.co/Y1Vn9kjk5N https://t.co/5CCxa5kMcU
Dr. John Cush RheumNow
3 years 1 month ago
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and
skin concerns.
https://t.co/lTfz2kUr51
Dr. John Cush RheumNow
3 years 1 month ago
NICE Guidelines on Gout Diagnosis and Management
NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.
https://t.co/a8iyCe3szJ https://t.co/6Jy7dOT4yX
Dr. John Cush RheumNow
3 years 1 month ago
Gout: diagnosis and management—summary of NICE guidance https://t.co/tVHkSMusk6 https://t.co/A7U1DlI7tO
Dr. John Cush RheumNow
3 years 1 month ago
SURPRISED? Psoriasis pts have a known increased risk of CV disease. But did you know several papers & metanalyses show increased risk of abdominal aortic aneurysm in PSO (HR 1.30), worse w/ dz activity; lost w/ age, female, DM? https://t.co/9ihyubUgCI https://t.co/W1JiXV0yOX https://t.co/Nq6aVBjPuK
Dr. John Cush RheumNow
3 years 1 month ago
Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/j00yWpBbq3 https://t.co/7BK2mopssc
Dr. John Cush RheumNow
3 years 1 month ago
USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/1Opblbiz7B https://t.co/xSw2uPUoKK
Dr. John Cush RheumNow
3 years 1 month ago
Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
- Steroid use "for irAEs may not have a large deleterious effect on overall survival"
- DMARDs for irAE "a major drawback in the delay in the onset of response"
https://t.co/8o8JBMpqML https://t.co/bWuLT3zYPm
Dr. John Cush RheumNow
3 years 1 month ago
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5
Dr. John Cush RheumNow
3 years 1 month ago
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.
https://t.co/ZaWnjxiR3W https://t.co/8CElIxWk1v https://t.co/ZVayc3Qt1r
Dr. John Cush RheumNow
3 years 1 month ago
EULAR/ACR Classification in MDA5+ Myositis Patients
A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM.
https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G
Dr. John Cush RheumNow
3 years 1 month ago
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/szQmNPO0eu https://t.co/z4tdP4I1kc
Dr. John Cush RheumNow
3 years 1 month ago
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and
skin concerns.
https://t.co/lTfz2kUr51 https://t.co/jVp8Uk0uH5
Dr. John Cush RheumNow
3 years 1 month ago
Longitudinal study of 411 adult fibromyalgia pts showed that 73.2% had depression at enrollment. Higher depression scores at baseline predicted poorer functional outcomes. Effectively treated depression resulted in improved functioning at follow-up. https://t.co/D43r4Z5llU https://t.co/a9EgyJLHza
Dr. John Cush RheumNow
3 years 1 month ago
Head Scratcher? Study of UK Biobank cohort (n=380,380) shows those taking Rx Folate had increased risk of COVID-19 Dx (OR 1.51; 1.42–1.61) and Death (OR 2.64; 2.15–3.24). MTX use (+/- folate) had no increase in COVID or COVID death(1.07;0.57–1.98) https://t.co/MLE1sL7KG2 https://t.co/adoLO9qLON
Poster Hall